240 related articles for article (PubMed ID: 12663644)
1. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4.
Lodge AJ; Anderson JJ; Gullick WJ; Haugk B; Leonard RC; Angus B
J Clin Pathol; 2003 Apr; 56(4):300-4. PubMed ID: 12663644
[TBL] [Abstract][Full Text] [Related]
2. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.
Suo Z; Risberg B; Kalsson MG; Willman K; Tierens A; Skovlund E; Nesland JM
J Pathol; 2002 Jan; 196(1):17-25. PubMed ID: 11748637
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
4. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell JA; Rampaul RS; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
Br J Cancer; 2004 Oct; 91(8):1532-42. PubMed ID: 15480434
[TBL] [Abstract][Full Text] [Related]
5. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients.
Guddo F; Giatromanolaki A; Koukourakis MI; Reina C; Vignola AM; Chlouverakis G; Hilkens J; Gatter KC; Harris AL; Bonsignore G
J Clin Pathol; 1998 Sep; 51(9):667-71. PubMed ID: 9930070
[TBL] [Abstract][Full Text] [Related]
6. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.
Osaki A; Toi M; Yamada H; Kawami H; Kuroi K; Toge T
Am J Surg; 1992 Oct; 164(4):323-6. PubMed ID: 1357997
[TBL] [Abstract][Full Text] [Related]
8. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
[TBL] [Abstract][Full Text] [Related]
9. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
[TBL] [Abstract][Full Text] [Related]
11. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
Thor AD; Liu S; Edgerton S; Moore D; Kasowitz KM; Benz CC; Stern DF; DiGiovanna MP
J Clin Oncol; 2000 Sep; 18(18):3230-9. PubMed ID: 10986055
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.
Langer R; Von Rahden BH; Nahrig J; Von Weyhern C; Reiter R; Feith M; Stein HJ; Siewert JR; Höfler H; Sarbia M
J Clin Pathol; 2006 Jun; 59(6):631-4. PubMed ID: 16731604
[TBL] [Abstract][Full Text] [Related]
13. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
14. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma.
Vaidya P; Kawarada Y; Higashiguchi T; Yoshida T; Sakakura T; Yatani R
J Pathol; 1996 Feb; 178(2):140-5. PubMed ID: 8683379
[TBL] [Abstract][Full Text] [Related]
16. The importance of EGFR as a biomarker in molecular apocrine breast cancer.
Liu X; Feng C; Liu J; Liu J; Li C; Xu C; Niu Y
Hum Pathol; 2018 Jul; 77():1-10. PubMed ID: 29409930
[TBL] [Abstract][Full Text] [Related]
17. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
[TBL] [Abstract][Full Text] [Related]
18. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study.
Gasparini G; Gullick WJ; Maluta S; Dalla Palma P; Caffo O; Leonardi E; Boracchi P; Pozza F; Lemoine NR; Bevilacqua P
Eur J Cancer; 1994; 30A(1):16-22. PubMed ID: 7908213
[TBL] [Abstract][Full Text] [Related]
19. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
Wright C; Nicholson S; Angus B; Sainsbury JR; Farndon J; Cairns J; Harris AL; Horne CH
Br J Cancer; 1992 Jan; 65(1):118-21. PubMed ID: 1346366
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy and breast cancer: a population-based study.
Reed W; Hannisdal E; Skovlund E; Thoresen S; Lilleng P; Nesland JM
Virchows Arch; 2003 Jul; 443(1):44-50. PubMed ID: 12756565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
